Last reviewed · How we verify
Y150
At a glance
| Generic name | Y150 |
|---|---|
| Sponsor | Wuhan YZY Biopharma Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple Myeloma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Y150 CI brief — competitive landscape report
- Y150 updates RSS · CI watch RSS
- Wuhan YZY Biopharma Co., Ltd. portfolio CI